Harbour BioMed takes HBICE platform into global clinical testing with B7H4×CD3 bispecific HBM7004
HBM7004 can now enter clinical development in both China and the United States after NMPA and FDA IND clearances, putting Harbour BioMed’s B7H4-dependent T-cell engager into its first human test.